Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Assets (2016 - 2025)

Historic Assets for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $329.5 million.

  • Enanta Pharmaceuticals' Assets fell 548.96% to $329.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $329.5 million, marking a year-over-year decrease of 548.96%. This contributed to the annual value of $280.7 million for FY2025, which is 2546.65% down from last year.
  • According to the latest figures from Q4 2025, Enanta Pharmaceuticals' Assets is $329.5 million, which was down 548.96% from $280.7 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' 5-year Assets high stood at $495.2 million for Q2 2023, and its period low was $280.7 million during Q3 2025.
  • Moreover, its 5-year median value for Assets was $392.0 million (2022), whereas its average is $389.8 million.
  • In the last 5 years, Enanta Pharmaceuticals' Assets soared by 2854.39% in 2023 and then crashed by 2546.65% in 2025.
  • Enanta Pharmaceuticals' Assets (Quarter) stood at $440.6 million in 2021, then fell by 21.12% to $347.5 million in 2022, then rose by 23.3% to $428.5 million in 2023, then decreased by 18.64% to $348.6 million in 2024, then fell by 5.49% to $329.5 million in 2025.
  • Its Assets was $329.5 million in Q4 2025, compared to $280.7 million in Q3 2025 and $301.0 million in Q2 2025.